Evidence map›Paper›PMID 34916103›Full record

ArticleVaccine2022

Socioeconomic disadvantage and human papillomavirus (HPV) vaccination uptake.

Shaheen Kurani, Kathy L MacLaughlin, Robert M Jacobson, Jennifer L St Sauver, Gregory D Jenkins, Chun Fan, Debra J Jacobson, Jonathan Inselman, Xuan Zhu, Joan M Griffin and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 2 pooled it
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 68 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Observational
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Shaheen KuraniDivision of Health Care Delivery Research, Mayo Clinic, 200 First Street, SW, Rochester, MN 55905, USA. Electronic address: Kurani.Shaheen@mayo.edu.
Kathy L MacLaughlinDepartment of Family Medicine, Mayo Clinic, 200 First Street, SW, Rochester, MN 55905, USA. Electronic address: MacLaughlin.Kathy@mayo.edu.
Robert M JacobsonDepartment of Pediatric and Adolescent Medicine, Mayo Clinic, 200 First Street, SW, Rochester, MN 55905, USA; Department of Quantitative Health Sciences, Mayo Clinic, 200 First Street, SW, Rochester, MN 55905, USA. Electronic address: jacobson.robert@mayo.edu.
Jennifer L St SauverDepartment of Quantitative Health Sciences, Mayo Clinic, 200 First Street, SW, Rochester, MN 55905, USA. Electronic address: StSauver.Jennifer@mayo.edu.
Gregory D JenkinsDepartment of Quantitative Health Sciences, Mayo Clinic, 200 First Street, SW, Rochester, MN 55905, USA. Electronic address: Jenkins.Gregory@mayo.edu.
Chun FanDepartment of Quantitative Health Sciences, Mayo Clinic, 200 First Street, SW, Rochester, MN 55905, USA. Electronic address: Fan.Chun@mayo.edu.
Debra J JacobsonDepartment of Quantitative Health Sciences, Mayo Clinic, 200 First Street, SW, Rochester, MN 55905, USA. Electronic address: djacobsn@mayo.edu.
Jonathan InselmanDivision of Health Care Delivery Research, Mayo Clinic, 200 First Street, SW, Rochester, MN 55905, USA. Electronic address: aInselman.Jonathan@mayo.edu.
Xuan ZhuDivision of Health Care Delivery Research, Mayo Clinic, 200 First Street, SW, Rochester, MN 55905, USA. Electronic address: Zhu.Xuan@mayo.edu.
Joan M GriffinDivision of Health Care Delivery Research, Mayo Clinic, 200 First Street, SW, Rochester, MN 55905, USA. Electronic address: Griffin.Joan@mayo.edu.
Lila J Finney RuttenDepartment of Quantitative Health Sciences, Mayo Clinic, 200 First Street, SW, Rochester, MN 55905, USA. Electronic address: Rutten.Lila@mayo.edu.
Mayo Clinic · US

Funding

Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI AKHILESH PANDEY · 1985 to 2026
$151.3M
"Less Pain, Less Fuss, Right Now!" and "Make It Count!"- Multilevel Interventions for Patient, Parent, and Practice to Enhance Provider Recommendations for HPV VaccinationR01CA217889 · NCI · MAYO CLINIC ROCHESTER · PI GRIFFIN, JOAN M., JACOBSON, ROBERT M. · 2018 to 2023
$2.9M
Interdisciplinary Infrastructure for Aging Research: Rochester Epidemiology ProjectR33AG058738 · NIA · MAYO CLINIC ROCHESTER · PI LEBRASSEUR, NATHAN K, OLSON, JANET E · 2020 to 2022
$2.4M
NCI NIH HHS P30 CA015083NCI NIH HHS R01 CA217889NIA NIH HHS R33 AG058738
6 · The paper itself

Abstract

importanceDespite availability of safe and effective human papillomavirus (HPV) vaccines, vaccination uptake remains low in the U.S. Research examining the impact of neighborhood socioeconomic status on HPV vaccination may help target interventions.

objectiveTo examine the association between area deprivation and HPV vaccine initiation and completion. DESIGN, SETTING,

participantsRetrospective cohort study of individuals aged 11-18 years residing in the upper Midwest region. Receipt of HPV vaccination was examined over a three-year follow-up period (01/01/2016-12/31/2018). MAIN OUTCOMES AND MEASURES: Outcomes of interest were initiation and completion of HPV vaccination. Demographic data were collected from the Rochester Epidemiology Project (REP). Area-level socioeconomic disadvantage was measured by calculating an Area Deprivation Index (ADI) score for each person, a measure of socioeconomic disadvantage derived from American Community Survey data. Multivariable mixed effect Cox proportional hazards models were used to examine the association of ADI quartiles (Q1-Q4) with HPV vaccine series initiation and completion, given initiation.

resultsIndividuals residing in census block groups with higher deprivation had significantly lower likelihood of HPV vaccine initiation (Q2: HR = 0.91, 0.84-0.99 Q3: HR = 0.83, 0.76-0.90; Q4: HR = 0.84, 0.74-0.96) relative to those in the least-deprived block groups (Q1). Similarly, those living in block groups with higher deprivation had significantly lower likelihood of completion (Q2: HR = 0.91, 0.86-0.97; Q3: HR = 0.87, 0.81-0.94; Q4: HR = 0.82, 0.74-0.92) compared to individuals in the least-deprived block groups (Q1). CONCLUSIONS AND RELEVANCE: Lower probability of both HPV vaccine-series initiation and completion were observed in areas with greater deprivation. Our results can inform allocation of resources to increase HPV vaccination rates in our primary care practice and provide an example of leveraging public data to inform similar efforts across diverse health systems.

Indexed as

AlphapapillomavirusPapillomavirus InfectionsPapillomavirus VaccinesHumansRetrospective StudiesSocial ClassVaccinationPapillomavirus VaccinesPapillomavirus InfectionsPapillomavirus vaccinesSocial classSocioeconomic factorsVaccination

Identifiers

PMID34916103
PMCPMC8778948
OpenAlexW4200375930

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.